Advertisement

The Wolff-Parkinson-White Syndrome and the Risk of Sudden Death

  • Michael H. Gollob
  • Rafeeq Samie
  • David H. Birnie
  • Martin S. Green
  • Robert M. Gow
Chapter

Abstract

Over 80 years ago, Drs. Wolff, Parkinson and White described the ECG characteristics and arrhythmia vulnerability of a young cohort of individuals. The condition would soon bear their names, and through subsequent decades of clinical, anatomical and physiological observations, the Wolff-Parkinson-White syndrome fascinated the cardiology field.

In more recent years, the condition has become recognized as a potential cause of sudden cardiac death in previously well individuals. The genetic basis of a complex form of Wolff-Parkinson-White syndrome associated with metabolic storage disease has now been recognized. Lastly, the advent of catheter ablation therapy in the last 20 years has allowed for cure of this condition. This chapter will review the history of this common condition, the variants in anatomy and physiology, genetics, and association with sudden cardiac death.

Keywords

WPW Sudden death PRKAG2 Preexcitation Re-entry arrhythmia 

References

  1. 1.
    Wolff L, Parkinson J, White PD. Bundle branch block with short PR interval in healthy young people prone to paroxysmal tachycardia. Am Heart J. 1930;5:686–704.CrossRefGoogle Scholar
  2. 2.
    Wood FC, Wolferth CC, Geckeler GD. Histologic demonstration of accessory muscular connections between auricle and ventricle in a case of short P–R interval and prolonged QRS. Am Heart J. 1943;25:454–62.CrossRefGoogle Scholar
  3. 3.
    Ohnell RF. Pre-excitation, cardiac abnormality, pathophysiological, patho-anatomical and clinical studies of excitatory spread phenomenon bearing upon the problem of the WPW (Wolff, Parkinson, and White) electrocardiogram and paroxysmal tachycardia. Acta Med Scand. 1944;152:1–167.Google Scholar
  4. 4.
    Prinzmetal M. Accelerated conduction: the Wolff-Parkinson-White syndrome and related conditions. New York: Grune and Stratton; 1952.Google Scholar
  5. 5.
    Sodi-Pallares D, Cisneros F, Medrano GA, et al. Electrocardiographic diagnosis of myocardial infarction in the presence of bundle branch block (right and left), ventricular premature beats and Wolff-Parkinson-White syndrome. Prog Cardiovasc Dis. 1963;6:107–36.PubMedCrossRefGoogle Scholar
  6. 6.
    Durrer D, Schoo L, Schuilenburg RM, et al. The role of premature beats in the initiation and the termination of supraventricular tachycardia in the Wolff-Parkinson-White syndrome. Circulation. 1967;36:644–62.PubMedCrossRefGoogle Scholar
  7. 7.
    Wellens HJ, Schuilenburg RM, Durrer D. Electrical stimulation of the heart in patients with Wolff-Parkinson-White syndrome, type A. Circulation. 1971;43:99–114.PubMedCrossRefGoogle Scholar
  8. 8.
    Mines GR. On circulating excitations in heart muscles and their possible relationship to tachycardia and fibrillation. Proc Trans R Soc Can. 1914;8:43–52.Google Scholar
  9. 9.
    Cobb FR, Blumenschein SD, Sealy WC, et al. Successful surgical interruption of the bundle of Kent in a patient with Wolff-Parkinson-White syndrome. Circulation. 1968;38:1018–29.PubMedCrossRefGoogle Scholar
  10. 10.
    Morady F, Scheinmann MM. Transvenous catheter ablation of a posteroseptal accessory pathway in a patient with the Wolff-Parkinson-White syndrome. N Engl J Med. 1984;310:705–7.PubMedCrossRefGoogle Scholar
  11. 11.
    Jackman WM, Wang XZ, Friday KJ, et al. Catheter ablation of accessory atrioventricular pathways (Wolff-Parkinson-White syndrome) by radiofrequency current. N Engl J Med. 1991;334:1605–11.CrossRefGoogle Scholar
  12. 12.
    Calkins H, Sousa J, el Atassi R, et al. Diagnosis and cure of the Wolff-Parkinson-White syndrome or paroxysmal supraventricular tachycardias during a single electrophysiologic test. N Engl J Med. 1991;324:1612–8.PubMedCrossRefGoogle Scholar
  13. 13.
    Kuck KH, Schluter M, Geiger M, et al. Radiofrequency current catheter ablation of accessory atrioventricular pathways. Lancet. 1991;337:1557–61.PubMedCrossRefGoogle Scholar
  14. 14.
    Gollob MH, Green MS, Tang AS, et al. Identification of a gene responsible for familial Wolff-Parkinson-White syndrome. N Engl J Med. 2001;344:1823–31.PubMedCrossRefGoogle Scholar
  15. 15.
    De Bacquer D, De Backer G, Kornitzer M. Prevalences o ECG findings in large population samples of men and women. Heart. 2000;84:625–33.PubMedCrossRefGoogle Scholar
  16. 16.
    Dreifus LS, Haiat R, Watanabe Y, et al. Ventricular fibrillation – a possible mechanism of sudden death in patients with Wolff-Parkinson-White syndrome. Circulation. 1971;43:520–7.PubMedCrossRefGoogle Scholar
  17. 17.
    Petrellis B, Skanes AC, Klein GJ, Gollob MH, Krahn AD, Yee R. An unusual accessory pathway: anteroseptal to ventricular outflow region connection. J Cardiovasc Electrophysiol. 2005;16(5):546–51.PubMedCrossRefGoogle Scholar
  18. 18.
    Mah D, Miyake C, Clegg R, Collins KK, Cecchin F, Treidman JK, et al. Epicardial left atrial appendage and biatrial appendage accessory pathways. Heart Rhythm. 2010;7:1740–5.PubMedCrossRefGoogle Scholar
  19. 19.
    Shah MJ, Garabedian H, Garoutte MC, Cecchin F. Catheter ablation of a right atrial appendage to the right ventricle connection in a neonate. Pacing Clin Electrophysiol. 2001;24(9 Pt 1):1427–9.PubMedCrossRefGoogle Scholar
  20. 20.
    Tchou P, Lehmann MH, Jazayeri M, Akhtar M. Atriofascicular connection or a nodoventricular Mahaim fiber? Electrophysiologic elucidation of the pathway and associated reentrant circuit. Circulation. 1988;77:837–48.PubMedCrossRefGoogle Scholar
  21. 21.
    Klein GJ, Guiraudon GM, Kerr CR, et al. “Nodoventricular” accessory pathway: evidence for a distinct accessory atrioventricular pathway with atrioventricular node-like properties. J Am Coll Cardiol. 1988;11:1035–40.PubMedCrossRefGoogle Scholar
  22. 22.
    McClelland JH, Wang X, Beckman KJ, et al. Radiofrequency catheter ablation of right atriofascicular (Mahaim) accessory pathways guided by accessory pathway activation potentials. Circulation. 1994;89:2655–66.PubMedCrossRefGoogle Scholar
  23. 23.
    Sternick EB, Timmermans C, Sosa E, et al. The electrocardiogram during sinus rhythm and tachycardia in patients with Mahaim fibers. J Am Coll Cardiol. 2004;44(8):1626–35.PubMedCrossRefGoogle Scholar
  24. 24.
    Sun Y, Arruda M, Otomo K, et al. Coronary sinus-ventricular accessory connections producing posteroseptal and left posterior ­accessory pathways: incidence and electrophysiological identification. Circulation. 2002;106:1362–7.PubMedCrossRefGoogle Scholar
  25. 25.
    Guiraudon GM, Guiraudon CM, Klein GJ, et al. The coronary sinus diverticulum: a pathologic entity associated with Wolff-Parkinson-White syndrome. Am J Cardiol. 1988;62:733–5.PubMedCrossRefGoogle Scholar
  26. 26.
    Mahaim I, Benatt A. Nouvelles recherches sur les connexions superieures de la branche gauche du faisceau de His-Tawara avec la cloison interventriculaire. Cardiologia. 1937;1:61–73.CrossRefGoogle Scholar
  27. 27.
    Gallagher JJ, Smith WM, Kasell JH, et al. Role of Mahaim fibers in cardiac arrhythmias in man. Circulation. 1981;64:176–89.PubMedCrossRefGoogle Scholar
  28. 28.
    Sternick EB, Gerken LM, Vrandecic MO, Wellens HJJ. Fasciculoventricular pathways: clinical and electrophysiologic characteristics of a variant of preexcitation. J Cardiovasc Electrophysiol. 2003;14(10):1057–63.PubMedCrossRefGoogle Scholar
  29. 29.
    Oh S, Choi YS, Choi EK, et al. Electrocardiographic characteristics of fasciculoventricular pathways. Pacing Clin Electrophysiol. 2005;28:25–8.PubMedCrossRefGoogle Scholar
  30. 30.
    Follath F, Hallidie-Smith KA. Unusual electrocardiographic changes in Ebstein’s anomaly. Br Heart J. 1972;34:513–9.PubMedCrossRefGoogle Scholar
  31. 31.
    Razzouk AJ, Gow R, Finley J, Murphy D, Williams WG. Surgically created Wolff-Parkinson-White syndrome after Fontan operation. Ann Thorac Surg. 1992;54:974–7.PubMedCrossRefGoogle Scholar
  32. 32.
    Blomstrom-Lundqvist C, Scheinman MM, Aliot EM, et al. ACC/AHA/ESC guidelines for the management of patients with supraventricular arrhythmias – executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to develop guidelines for the management of patients with supraventricular arrhythmias) developed in collaboration with NASPE-Heart Rhythm Society. J Am Coll Cardiol. 2003;42:1493–531.PubMedCrossRefGoogle Scholar
  33. 33.
    Silka MJ, Hardy BG, Menashe VD, Morris CD. A population-based prospective evaluation of risk of sudden cardiac death after operation for common congenital heart defects. J Am Coll Cardiol. 1998;32:245–51.PubMedCrossRefGoogle Scholar
  34. 34.
    Oh JK, Holmes Jr DR, Hayes DL, Porter CB, Danielson GK. Cardiac arrhythmias in patients with surgical repair of Ebstein’s anomaly. J Am Coll Cardiol. 1985;6:1351–7.PubMedCrossRefGoogle Scholar
  35. 35.
    Harnischfeger WW. Hereditary occurrence of the pre-excitation (Wolff-Parkinson-White) syndrome with re-entry mechanism and concealed conduction. Circulation. 1959;19:28–40.PubMedCrossRefGoogle Scholar
  36. 36.
    Vidaillet Jr HJ, Pressley JC, Henke E, et al. Familial occurrence of accessory atrioventricular pathways (preexcitation syndrome). N Engl J Med. 1987;317:65–9.PubMedCrossRefGoogle Scholar
  37. 37.
    Cherry JM, Green MS. Familial cardiomyopathy: a new autosomal dominant form (abstract). Clin Invest Med. 1986;9:B31.Google Scholar
  38. 38.
    Gollob MH, Seger JJ, Gollob TN, et al. Novel PRKAG2 mutation responsible for the genetic syndrome of ventricular preexcitation and conduction system disease with childhood onset and absence of cardiac hypertrophy. Circulation. 2001;104:3030–3.PubMedCrossRefGoogle Scholar
  39. 39.
    Gollob MH, Green MS, Tang AS, Roberts R. PRKAG2 cardiac syndrome: familial ventricular preexcitation, conduction system disease, and cardiac hypertrophy. Curr Opin Cardiol. 2002;17:229–34.PubMedCrossRefGoogle Scholar
  40. 40.
    MacRae CA, Ghasia N, Kass S, et al. Familial hypertrophic cardiomyopathy with Wolff-Parkinson-White syndrome maps to a locus on chromosome 7q3. J Clin Invest. 1995;96:1216–20.PubMedCrossRefGoogle Scholar
  41. 41.
    Sinha SC, Nair M, Gambhir DS, et al. Genetically transmitted ventricular pre-excitation in a family with hypertrophic cardiomyopathy. Indian Heart J. 2000;52:76–8.PubMedGoogle Scholar
  42. 42.
    Gollob MH. Glycogen storage disease as a unifying mechanism of disease in the PRKAG2 cardiac syndrome. Biochem Soc Trans. 2003;31:228–31.PubMedCrossRefGoogle Scholar
  43. 43.
    Arad M, Moskowitz IP, Patel VV, et al. Transgenic mice overexpressing mutant PRKAG2 define the cause of Wolff-Parkinson-White syndrome in glycogen storage cardiomyopathy. Circulation. 2003;107:2850–6.PubMedCrossRefGoogle Scholar
  44. 44.
    Sidhu JS, Rajawat YS, Rami TG, et al. Transgenic mouse model of ventricular preexcitation and atrioventricular reentrant tachycardia induced by an AMP-activated protein kinase loss-of-function mutation responsible for Wolff-Parkinson-White syndrome. Circulation. 2005;111:21–9.PubMedCrossRefGoogle Scholar
  45. 45.
    Gollob MH, Green MS, Veinot JP. Altered AMP-activated protein kinase activity and pathologic cardiac disease. Heart Metab. 2006;32:28–31.Google Scholar
  46. 46.
    Burwinkel B, Scott JW, Buhrer C, et al. Fatal congenital heart glycogenosis caused by a recurrent activating R531Q mutation in the gamma-2 subunit of AMP-activated protein kinase (PRKAG2), not by phosphorylase kinase deficiency. Am J Hum Genet. 2005;76:1034–49.PubMedCrossRefGoogle Scholar
  47. 47.
    Wessels A, Markman MWM, Vermeulen JLM, et al. The development of the atrioventricular junction in the human heart. Circ Res. 1996;78:110–7.PubMedCrossRefGoogle Scholar
  48. 48.
    Bulkley BH, Hutchins GM. Pompe’s disease presenting as hypertrophic myocardiopathy with Wolff-Parkinson-White syndrome. Am Heart J. 1978;96:246–52.PubMedCrossRefGoogle Scholar
  49. 49.
    Komukai K, Brette F, Orchard CH. Electrophysiological response of rat ventricular myocytes to acidosis. Am J Physiol Heart Circ Physiol. 2002;283:H715–24.PubMedGoogle Scholar
  50. 50.
    Padanilam BJ, Lu T, Hoshi T, et al. Molecular determinants of intracellular pH modulation of human Kv1.4 N-type inactivation. Mol Pharmacol. 2002;62:127–34.PubMedCrossRefGoogle Scholar
  51. 51.
    Lalani SR, Thakuria JV, Cox GF, Wang X, et al. 20p12.3 microdeletion predisposes to Wolff-Parkinson-White syndrome with variable neurocognitive deficits. J Med Genet. 2009;46:168–75.PubMedCrossRefGoogle Scholar
  52. 52.
    Munger TM, Packer DL, Hammill SC, et al. A population study of the natural history of Wolff-Parkinson-White syndrome in Olmsted County, Minnesota, 1953–1989. Circulation. 1993;87:866–73.PubMedCrossRefGoogle Scholar
  53. 53.
    Fitzsimmons PJ, McWhirter PD, Peterson DW, et al. The natural history of Wolff-Parkinson-White syndrome in 228 military aviators: a long term follow-up of 22 years. Am Heart J. 2001;142:530–6.PubMedCrossRefGoogle Scholar
  54. 54.
    Pappone C, Santtinelli V, Rosanio S, et al. Usefulness of invasive electrophysiology testing to stratify the risk of arrhythmic events in asymptomatic patients with Wolff-Parkinson-White pattern: results from a large prospective long-term follow-up study. J Am Coll Cardiol. 2003;41:239–44.PubMedCrossRefGoogle Scholar
  55. 55.
    Maron BJ, Roberts WC, McAllistair HA, et al. Sudden death in young athletes. Circulation. 1980;62:218–29.PubMedCrossRefGoogle Scholar
  56. 56.
    Maron BJ, Epstein SE, Roberts WC. Causes of sudden death in competitive athletes. J Am Coll Cardiol. 1986;7:204–14.PubMedCrossRefGoogle Scholar
  57. 57.
    Topaz O, Perin E, Cox M, et al. Young adult survivors of sudden cardiac death: analysis of invasive evaluation of 22 subjects. Am Heart J. 1989;118:281–7.PubMedCrossRefGoogle Scholar
  58. 58.
    Basso C, Corrado D, Rossi L, et al. Ventricular preexcitation in children and young adults: atrial myocarditis as a possible trigger of sudden death. Circulation. 2001;103:269–75.PubMedCrossRefGoogle Scholar
  59. 59.
    Strasberg B, Ashley WW, Wyndham CRC, et al. Treadmill exercise testing in the Wolff-Parkinson-White syndrome. Am J Cardiol. 1980;45:742–8.PubMedCrossRefGoogle Scholar
  60. 60.
    Levy S, Brooustet JP, Clementy J, et al. Value of noninvasive techniques in the Wolff-Parkinson-White syndrome with particular reference to exercise testing. In: Levy S, Scheinmann M, editors. Cardiac arrhythmia from diagnosis to therapy. Mount Kisco: Futura; 1984. p. 301–12.Google Scholar
  61. 61.
    Critelli G, Grassi G, Perticone F, et al. Transesophageal pacing for prognostic evaluation of preexcitation syndromes and assessment of protective therapy. Am J Cardiol. 1983;51:513–8.PubMedCrossRefGoogle Scholar
  62. 62.
    Sharma AD, Yee R, Guiraudon G, Klein GJ. Sensitivity and specificity of invasive and noninvasive testing for risk of sudden death in Wolff-Parkinson-White syndrome. J Am Coll Cardiol. 1987;10:373–81.PubMedCrossRefGoogle Scholar
  63. 63.
    Klein GJ, Bashore TM, Sellers TD, et al. Ventricular fibrillation in the Wolff-Parkinson-White syndrome. N Engl J Med. 1979;301:1080–5.PubMedCrossRefGoogle Scholar
  64. 64.
    Bromberg BI, Lindsay BD, Cain ME, Cox JL. Impact of clinical history and electrophysiologic characterization of accessory pathways on management strategies to reduce sudden death among children with Wolff-Parkinson-White syndrome. J Am Coll Cardiol. 1996;27:690–5.PubMedCrossRefGoogle Scholar
  65. 65.
    Campbell RM, Strieper MJ, Frias PA, et al. Survey of current practice of pediatric electrophysiologists for asymptomatic Wolff-Parkinson-White syndrome. Pediatrics. 2003;111:e245–7.PubMedCrossRefGoogle Scholar
  66. 66.
    Nanthakumar K, Bergfeldt L, Darpo B. Assessment of accessory pathway and atrial refractoriness by transoesophageal and intracardiac atrial stimulation: an analysis of methodological agreement. Europace. 1999;1:55–62.PubMedCrossRefGoogle Scholar
  67. 67.
    Manolis AS, Katsaros C, Cokkinos DV. Electrophysiological and electropharmacological studies in pre-excitation syndromes: results with propafenone therapy and isoproterenol infusion testing. Eur Heart J. 1992;13:1489–95.PubMedGoogle Scholar
  68. 68.
    Helmy I, Scheinman MM, Herre JM, et al. Electrophysiologic effects of isoproterenol in patients with atrioventricular reentrant tachycardia treated with flecainide. J Am Coll Cardiol. 1990;16:1649–55.PubMedCrossRefGoogle Scholar
  69. 69.
    Henthorn RW, Waldo AL, Anderson JL, et al. Flecainide acetate prevents recurrence of symptomatic paroxysmal supraventricular tachycardia. The Flecainide Supraventricular Tachycardia Study Group. Circulation. 1991;83:119–25.PubMedCrossRefGoogle Scholar
  70. 70.
    A randomized, placebo-controlled trial of propafenone in the prophylaxis of paroxysmal supraventricular tachycardia and paroxysmal atrial fibrillation. UK Propafenone PSVT Study Group. Circulation. 1995;92:2550–7.Google Scholar
  71. 71.
    Perry SC, Garson Jr A. Flecainide acetate for treatment of tachyarrhythmias in children: review of world literature on efficacy, safety, and dosing. Am Heart J. 1992;124:1614–21.PubMedCrossRefGoogle Scholar
  72. 72.
    Nunez F, Ruiz-Granell R, Martinez-Costa C, Morell S, Brines J. Safety and efficacy of flecainide in the treatment of symptomatic children with Wolff-Parkinson-White syndrome. Pediatr Cardiol. 2010;31:1162–5.PubMedCrossRefGoogle Scholar
  73. 73.
    Kunze KP, Schluter M, Kuck KH. Sotalol in patients with Wolff-Parkinson-White syndrome. Circulation. 1987;75:1050–7.PubMedCrossRefGoogle Scholar
  74. 74.
    Tuzcu EM, Gilbo J, Masterson M, Maloney JD. The usefulness of amiodarone in management of refractory supraventricular tachyarrhythmias. Cleve Clin J Med. 1989;56:238–42.PubMedCrossRefGoogle Scholar
  75. 75.
    Friedman RA, Walsh EP, Silka MJ, et al. NASPE Expert consensus conference: radiofrequency catheter ablation in children with and without congenital heart disease. Report of the writing committee. North American Society of Pacing and Electrophysiology. Pacing Clin Electrophysiol. 2002;25:1000–17.PubMedCrossRefGoogle Scholar
  76. 76.
    Hindricks G. The Multicentre European Radiofrequency Survey (MERFS): complications of radiofrequency catheter ablation of arrhythmias The Multicentre European Radiofrequency Survey (MERFS) investigators of the Working Group on Arrhythmias of the European Society of Cardiology. Eur Heart J. 1993;14:1644–53.PubMedCrossRefGoogle Scholar
  77. 77.
    Kugler JD, Danford DA, Houston KS, et al. Pediatric radiofrequency catheter ablation registry success, fluoroscopy time, and complication rates for supraventricular tachycardias: comparison of early and recent eras. J Cardiovasc Electrophysiol. 2002;13:336–41.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag London 2013

Authors and Affiliations

  • Michael H. Gollob
    • 1
  • Rafeeq Samie
    • 2
  • David H. Birnie
    • 2
  • Martin S. Green
    • 2
  • Robert M. Gow
    • 3
  1. 1.Arrhythmia Research Laboratory, Division of Cardiology, Department of MedicineUniversity of Ottawa Heart InstituteOttawaCanada
  2. 2.Division of Cardiology, Department of MedicineUniversity of Ottawa Heart InstituteOttawaCanada
  3. 3.Division of Cardiology, Department of MedicineChildren’s Hospital of Eastern Ontario, University of OttawaOttawaCanada

Personalised recommendations